LOS ANGELES--(BUSINESS WIRE)--Response Genetics Inc. (Nasdaq:RGDX), a company focused on the development and sale of molecular diagnostic tests for cancer, will announce the results of studies in bladder cancer, colon cancer and colorectal cancer that identify genes associated with positive chemotherapy outcome and tumor recurrence. Results will be presented during the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, which will be held May 29 to June 2.
